Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Mycetoma Indication Strategy Report 2026: CYP51, Trials and Deals
3 August 2026
2026 Mycetoma indication strategy covering epidemiology, CYP51 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Dracunculiasis Indication Strategy Report 2026: Glutamate-gated chloride channel, Trials and Deals
3 August 2026
2026 Dracunculiasis indication strategy covering epidemiology, Glutamate-gated chloride channel biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Chromoblastomycosis Indication Strategy Report 2026: CYP51, Trials and Deals
3 August 2026
2026 Chromoblastomycosis indication strategy covering epidemiology, CYP51 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Loiasis Indication Strategy Report 2026: Wolbachia, Trials and Deals
3 August 2026
2026 Loiasis indication strategy covering epidemiology, Wolbachia biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Congenital toxoplasmosis Indication Strategy Report 2026: DHFR, Trials and Deals
3 August 2026
2026 Congenital toxoplasmosis indication strategy covering epidemiology, DHFR biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Visceral larva migrans Indication Strategy Report 2026: Beta-tubulin, Trials and Deals
3 August 2026
2026 Visceral larva migrans indication strategy covering epidemiology, Beta-tubulin biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Granulomatous amebic encephalitis Indication Strategy Report 2026: CYP51, Trials and Deals
3 August 2026
2026 Granulomatous amebic encephalitis indication strategy covering epidemiology, CYP51 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Naegleria fowleri infection Indication Strategy Report 2026: CYP51, Trials and Deals
3 August 2026
2026 Naegleria fowleri infection indication strategy covering epidemiology, CYP51 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Microsporidiosis Indication Strategy Report 2026: Methionine aminopeptidase, Trials and Deals
3 August 2026
2026 Microsporidiosis indication strategy covering epidemiology, Methionine aminopeptidase biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Toxoplasmic encephalitis Indication Strategy Report 2026: DHFR, Trials and Deals
3 August 2026
2026 Toxoplasmic encephalitis indication strategy covering epidemiology, DHFR biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Relapsing fever Indication Strategy Report 2026: Vmp, Trials and Deals
3 August 2026
2026 Relapsing fever indication strategy covering epidemiology, Vmp biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Plague Indication Strategy Report 2026: F1 antigen, Trials and Deals
3 August 2026
2026 Plague indication strategy covering epidemiology, F1 antigen biology, active trials, transactions, unmet need, competition and market attractiveness.